Effectiveness of light emitting diode phototherapy for direct coombs positive newborns
Abstract
Background: Phototherapy is the most frequently used treatment when serum bilirubin levels exceed physiological limits. The direct antiglobulin titer (DAT) test is regarded as the cornerstone of diagnosis of immune hemolytic disease of the newborn.
Methods: Patients with hyperbilirubinemia who were born in our hospital and whose gestational age was over 35 weeks were enrolled. DAT positive and DAT negative patients were compared in terms of light emitting diode (LED) phototherapy efficacy.
Results: Seventy-seven cases were DAT-negative and 72 were DAT-positive. No statistically significant differences were found for the duration of phototherapy and hospitalization between the DAT-positive and negative groups. In the DAT-positive group, the phototherapy needs of the patients were determined to occur at an earlier stage (postnatal age 1.4 day, p<0.05), and the rate of patients requiring exchange transfusion, blood transfusion and intravenous immunoglobulin was found to be statistically significant higher in DAT-positive infants.
Conclusions: Although LED phototherapy is effective in DAT-positive patients, the need for exchange transfusion and intravenöz immunoglobulin (IVIG) shows that there is still a need for more effective phototherapy in these patients.
Keywords
References
- 1. Murray NA, Roberts IA. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2007;92:F83–88
- 2. Madan A, Huntsinger K, Burgos A, Benitz WE. Readmission for newborn jaundice: the value of the Coomb’s test in predicting the need for phototherapy. Clin. Pediatr 2004;43: 63–8
- 3. Ozolek JA, Watchko JF, Mimouni F. Prevalence and lack of clinical significance of blood group incompatibility in mothers with blood type A or B. J Pediatr 1994;125:87–91
- 4. Meberg A, Johansen KB. Screening for neonatal hyperbilirubinaemia and ABO alloimmunization at the time of testing for phenylketonuria and congenital hypothyreosis. Acta Paediatr 1998;87:1269–1274
- 5. Maisels MJ, Kring E. Risk of sepsis in newborns with severe hyperbilirubinemia. Pediatrics 1992;90:741–743
- 6. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297– 316
- 7. Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or =35 weeks’ gestation: an update with clarifications. Pediatrics 2009; 124:1193– 1198
- 8. Kaplan M, Hammerman C, Vreman HJ, Wong RJ, Stevenson DK. Direct antiglobulin titer strength and hyperbilirubinemia. Pediatrics 2014;134. e1340e4
Details
Primary Language
English
Subjects
Clinical Sciences
Journal Section
Research Article
Authors
Nilüfer Okur
*
0000-0002-0027-0532
Türkiye
Nurdan Uras
0000-0003-3382-7226
Türkiye
Ömer Ertekin
0000-0002-7846-7634
Türkiye
Şerife Suna Oğuz
0000-0002-1870-0983
Türkiye
Publication Date
August 29, 2019
Submission Date
February 11, 2019
Acceptance Date
June 14, 2019
Published in Issue
Year 2019 Volume: 16 Number: 2